PX’Therapeutics and RELIEF THERAPEUTICS Holding AG announce a strategic collaboration agreement for the recombinant production of atexakin alfa
PX’Therapeutics, a subsidiary of the Aguettant group, a company that specializes in the customer-tailored development of recombinant proteins, and RELIEF THERAPEUTICS Holding AG (“Relief”,SIX:RLF), a biotechnology company dedicated to the clinical development of innovative molecules for the treatment of certain diabetes-related complications, respiratory disorders and rare diseases, have announced today a strategic collaboration agreement for the production of atexakin alfa, a low-dose formulation of the recombinant human protein interleukin 6.
Diary - News
All news PX’Therapeutics and RELIEF THERAPEUTICS Holding AG announce a strategic collaboration agreement for the recombinant production of atexakin alfa 
